ReviewInternational journal of women's health2023
Vasomotor Symptoms During Menopause: A Practical Guide on Current Treatments and Future Perspectives.
Review in International journal of women's health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Effectiveness and safety of commercial Chinese polyherbal preparations combined with menopausal hormone therapy for perimenopausal symptoms: a network meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2026Pooled it
- Brazilian Guideline on Menopausal Cardiovascular Health - 2024.Arquivos brasileiros de cardiologia · 2024Guideline
- An examination into the safety and efficacy of Khapregesic®, a Khaya senegalensis preparation, on physical and psychological wellbeing in women experiencing menopausal symptoms: a randomised, double-blind, placebo-controlled trial.Frontiers in reproductive health · 2026Trial
- Novel Application of Oral Postbiotics for Skin Condition in Healthy Middle-Aged Women: A Randomized, Double-Blind, and Placebo-Controlled Study.Journal of cosmetic dermatology · 2025Trial
- A randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy of the synbiotic medical food, SBD111, for the clinical dietary management of bone loss in menopausal women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Trial
- Development and Initial Psychometric Validation of the Multidimensional Menopausal Burden Questionnaire (MMBQ-44) in a Sample of Romanian Women.Diagnostics (Basel, Switzerland) · 2026Article
- Comparison of Health, Quality of Life, and Psychological and Cognitive Function Between Perimenopausal and Postmenopausal Women: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
- Exploring the Health Effects of Phytoestrogens.Metabolites · 2026Review
- Clinical review: Menopause hormone therapy in weight management.Obesity pillars · 2026Review
- Review
- The effects of menopausal hormone therapy on cardiovascular disease, cancer, cognition and depression in younger women: A systematic review.JRSM open · 2026Review
- Diet, the Gut Microbiome, and Estrogen Physiology: A Review in Menopausal Health and Interventions.Nutrients · 2026Review
- European Code Against Cancer, 5th edition - hormone replacement therapy, other common medical therapies and cancer.Molecular oncology · 2026Review
- Functional foods and their potential impact on women's health in Chile.Frontiers in nutrition · 2026Review
- Empowering menopausal women to adopt climate-adaptive health behaviors and reduce climate-sensitive health outcomes: an IMB model-based quasi-experimental study.Frontiers in public health · 2026Article
- A synbiotic medical food improves gut barrier function, reduces immune responses, and inhibits osteoclast activity in models of postmenopausal bone loss aligned with clinical outcomes.Journal of functional foods · 2025Article
- Insulin levels early in perimenopause inform vasomotor symptom incidence across the menopausal transition.medRxiv : the preprint server for health sciences · 2025Article
- An Evidence-Based Approach to the Management of Primary Ovarian Insufficiency in Adolescents and Young Women.Life (Basel, Switzerland) · 2025Article
- The effects of estradiol on subcortical brain volumes in perimenopausal-onset depression.Journal of affective disorders · 2025Article
- The effects of transdermal estrogens combined with Medroxyprogesterone Acetate on cardiovascular disease risk factors in postmenopausal women: a meta-analysis of randomized controlled trials.Diabetology & metabolic syndrome · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vasomotor symptoms affect as many as 80% of midlife women, but only about one in four women receive treatment due to many factors. Menopausal hormone therapy remains the most effective treatment for vasomotor symptoms, and current professional guidelines conclude that the benefits of treatment typically outweigh the risks for healthy, symptomatic women under age 60 years and those within 10 years from their final menstrual period. For women with medical comorbidities, an individualized approach to treatment is recommended. For women who cannot use or choose not to use menopausal hormone therapy, there are many evidence-based non-hormonal options available including pharmacologic therapies. This review aims to summarize treatment options for bothersome vasomotor symptoms to guide clinicians caring for midlife women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.